Exonbio has developed SARS-CoV-2 Spike recombinant monoclonal antibodies for the global IVD and research communities in support of efforts to combat the pandemic. By using Exonbio’s SPIN® technology platform, highly specific antibodies from plasma cells are generated against spike protein of SARS-CoV-2. These high affinity and sensitivity antibodies can be used for antigen detection of diagnostic kit development.
SARS-CoV-2 Spike S1 protein IgG mAbs
Clone ID | Isotype | Species | EC50 (ng/ml) |
SP2B6 | IgG,K | Rabbit | 6.228 |
SP2E6 | IgG,K | Rabbit | 7.219 |
SP4C3 | IgG,K | Rabbit | 6.594 |
SP6C3 | IgG,K | Rabbit | 2.908 |
SP6F6 | IgG,K | Rabbit | 2.247 |
SP6B2 | IgG,K | Rabbit | 5.861 |
SP6D2 | IgG,K | Rabbit | 3.735 |
SP6D6 | IgG,K | Rabbit | 2.194 |
SP6E4 | IgG,K | Rabbit | 2.604 |
Please reach out to us at antibody@exonbio.com for more information about our SARS-CoV-2 Spike S1 protein monoclonal antibodies.
Epitope Mapping
High-affinity monoclonal antibodies that fall in different epitope bins allow for antibody pairing for the development of ELISA kit. For detailed Spike monoclonal pairing & clone information contact us.

Validation Data
ELISA: Spike S1 protein IgG mAbs are high affinity, with EC50 range between 2.1-7.2 ng/ml.

Neutralization Assay: The S1-targeting monoclonal antibodies blocks the interaction between receptor binding domain and ACE2 receptor and exhibits high levels of neutralization activity.
